EphA2 antagonism alleviates LPS-induced acute lung injury via Nrf2/HO-1, TLR4/MyD88 and RhoA/ROCK pathways

Int Immunopharmacol. 2019 Jul:72:176-185. doi: 10.1016/j.intimp.2019.04.008. Epub 2019 Apr 12.

Abstract

Eph receptor tyrosine kinases have a wide range of biological functions and have gradually been recognized increasingly as key regulators of inflammation and injury diseases. Although previous studies suggested that EphA2 receptor may be involved in the regulation of inflammation and vascular permeability in injured lung, the detailed effects of EphA2 on LPS-induced acute lung injury (ALI) are still inadequate and the underlying mechanism remains poorly understood. In this study, we detected the effects of EphA2 antagonism on inflammation, pulmonary vascular permeability and oxidative stress in LPS-induced ALI and investigate the potential mechanism. Our results showed that EphA2 antagonism markedly inhibited the cytokines release and inflammatory cells infiltration in BALF, prevented the LPS-induced elevations of MPO activity and MDA level in lung tissues. Our study also found that EphA2 antagonism significantly decreased the wet/dry ratios, reduced the Evans blue albumin extravasation in lung tissues and obviously alleviated the LPS-induced increment of pulmonary vascular permeability. Mechanistically, EphA2 antagonism significantly increased the activation of Nrf2 along with its target antioxidant enzyme HO-1 and inhibited the expressions of TLR4/MyD88 in lung tissues and A549 alveolar epithelial cells. Furthermore, EphA2 antagonism dramatically inhibited the LPS-evoked activations of RhoA/ROCK in lung tissues. In conclusion, our data indicate that EphA2 receptor plays an essential role in LPS-induced ALI and EphA2 antagonism has protective effects against LPS-induced ALI via Nrf2/HO-1, TLR4/MyD88 and RhoA/ROCK pathways. These results suggest that antagonism of EphA2 may be an effective therapeutic strategy for the treatment of ALI.

Keywords: Acute lung injury; Acute respiratory distress syndrome; EphA2; Nrf2; RhoA; TLR4.

MeSH terms

  • A549 Cells
  • Acute Lung Injury / drug therapy*
  • Acute Lung Injury / metabolism
  • Acute Lung Injury / pathology
  • Animals
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Bronchoalveolar Lavage Fluid / chemistry
  • Heme Oxygenase (Decyclizing) / metabolism
  • Humans
  • Lipopolysaccharides
  • Lung / drug effects
  • Lung / metabolism
  • Lung / pathology
  • Male
  • Malondialdehyde / metabolism
  • Myeloid Differentiation Factor 88 / metabolism
  • NF-E2-Related Factor 2 / metabolism
  • Oxidative Stress / drug effects
  • Peroxidase / metabolism
  • Rats, Sprague-Dawley
  • Receptor, EphA2 / antagonists & inhibitors*
  • Receptor, EphA2 / immunology
  • Signal Transduction / drug effects
  • Toll-Like Receptor 4 / metabolism
  • Tumor Necrosis Factor-alpha / metabolism
  • rho GTP-Binding Proteins / metabolism
  • rho-Associated Kinases / metabolism

Substances

  • Antibodies, Monoclonal
  • Lipopolysaccharides
  • Myd88 protein, rat
  • Myeloid Differentiation Factor 88
  • NF-E2-Related Factor 2
  • Nfe2l2 protein, rat
  • Tlr4 protein, rat
  • Toll-Like Receptor 4
  • Tumor Necrosis Factor-alpha
  • Malondialdehyde
  • Peroxidase
  • Heme Oxygenase (Decyclizing)
  • Hmox1 protein, rat
  • Receptor, EphA2
  • rho-Associated Kinases
  • RhoA protein, rat
  • rho GTP-Binding Proteins